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Background: What was the relationship of Fuzheng Huayu recipe (FZHY) inhibiting hepatocyte apoptosis and HSC
activation at different stage of liver fibrosis? In order to answer this question, the study was carried out to
dynamically observe FZHY’s effect on hepatocyte apoptosis and HSC activation and further explored underling
mechanism of FZHY against hepatocyte apoptosis.
Methods: Mice were randomly divided into four groups: normal, model, FZHY, and N-acetylcystein (NAC) groups.
Acute hepatic injury and liver fibrosis in mice were induced by CCl4. Three days before the first CCl4 injection, treatment
with FZHY powder or NAC respectively was started. In vitro, primary hepatocytes were pretreated with FZHY medicated
serum or Z-VAD-FMK and then incubated with ActD and TNF-α. Primary HSCs were treated with DNA from apoptotic
hepatocytes incubated by Act D/TNF-α or FZHY medicated. Liver sections were analyzed for HE staining and
immunohistochemical evaluation of apoptosis. Serum ALT and AST, Alb content and TNF-α expression in liver tissue
were detected. Hyp content was assayed and collagen deposition was visualized. Expressions of α-SMA and type I
collagen were analyzed by immunofluorescence and immunoblotting. Flow cytometry, immunofluorescence, and DNA
ladder for hepatocyte apoptosis and immunoblotting for TNF-R1, Bcl-2 and Bax were also analyzed.
Results: Mice showed characteristic features of massive hepatocytes apoptosis in early stage of liver injury and
developed severe hepatic fibrosis in later phase. FZHY treatment significantly alleviated acute liver injury and
hepatocyte apoptosis, and inhibited liver fibrosis by decreasing α-SMA expression and hepatic Hyp content. In vitro,
primary hepatocytes were induced by TNF-α and Act D. The anti-apoptotic effect of FZHY was generated by reducing
TNFR1 expression and balancing the expressions of Bcl-2 and Bax. Meanwhile, the nuclear DNA from apoptotic
hepatocytes stimulated HSC activation in a dose dependent manner, and the DNA from apoptotic hepatocytes treated
with FZHY or Z-VAD-FMK reduced HSC activation and type I collagen expression.
Conclusion: These findings suggested that FZHY suppressed hepatocyte apoptosis through regulating mediators in
death receptor and mitochondrial pathways, and the effect of FZHY on hepatocyte apoptosis might play an important
role in inhibiting liver fibrosis.
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Liver fibrosis is a wound healing process elicited by
chronic liver injury [1]. Liver injuries, such as hepatocytic
inflammatory necrosis and apoptosis, are the precursors of
liver fibrosis [2]. Chronic liver injury of various etiologies* Correspondence: chenghailiu@hotmail.com
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differentiation of hepatic stellate cells (HSCs) into an ac-
tivated myofibroblast (α-SMA-expressing) and thereby
acquires fibrogenic properties producing extracellular
matrix (ECM) proteins with an upregulation of profibro-
genic cytokines such as TGF-β [1]. Hepatocyte apoptosis
triggers HSC activation either directly by phagocytosis of
the apoptotic bodies [3], or indirectly by damage-
associated molecular patterns inducing the migration and
activation of HSC [4]. Thus rational treatment approaches
for liver fibrosis may include drugs that target hepatocyte
apoptosis, HSC activation, or both.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cidated much more clearly, however, progress in the
treatment of liver fibrosis remains alarmingly slow [5,6].
In the recent years, searching effective preparation against
hepatic fibrosis from traditional chinese medicine (TCM)
in China has achieved a big progress [7-9]. Fuzheng
Huayu recipe (FZHY) is one of the well studied anti-
fibrotic products in China. FZHY consists of six Chinese
medicinal herbs [10], namely Radix Salvia Miltiorrhizae
(Danshen), Cordyceps (Chongcao), Semen Persicae (Taoren),
Gynostemma Pentaphyllammak (Jiaogulan), Pollen Pini
(Songhuafen), Fructus Schisandrae Chinensis (Wuweizi). It
has been approved by SFDA as a drug and widely used to
treat hepatic fibrosis in China since 2002. And now its effi-
cacy against liver fibrosis was confirmed in phase II clin-
ical trial carried out in US (www.clinicaltrials.gov).
Previous studies have shown that FZHY exerts good
effects against liver fibrosis in both animal experiments
and clinical trials [11-14], the potential mechanisms of
which are well studied and summarized in a recent pub-
lished review [15]. Studies show that FZHY regulates
many aspects of hepatic fibrosis, among them, inhibition
of HSC activation is considered as a prominent effect
[16]. It is widely known that hepatocyte apoptosis plays
a pivotal role in hepatic fibrogenesis, and FZHY also
shows a good effect on hepatic inflammation as well as
hepatocyte apoptosis [17].While how the two mecha-
nisms contributed to FZHY’s efficacy on liver fibrosis at
different stage remained unclear. In this study, we car-
ried out in vivo and in vitro studies on dynamic changes
of hepatocyte apoptosis and HSC activation at different
stage of liver fibrosis and effect of FZHY on hepatocyte
apoptosis and HSC activation and further explored
underling mechanism of FZHY against hepatocyte apop-
tosis in the early stage of liver fibrosis.
Methods
Reagents
Carbon tetrachloride (CCl4) was supplied by National Phar-
maceutical Group Chemical Reagent Co., Ltd. (Shanghai,
China). Actinomycin D (ActD) was purchased from Appli-
Chem (Darmstadt, Germany). Tumor necrosis factor-
α (TNF-α) and TACSTM Annexin V-fluorescein iso-
thiocyanate (FITC) were obtained from R&D Systems
(Minneapolis, MN, USA). Rat TNF alpha ELISA Kit
was purchased from ThermoFisher Scientific Inc. In
Situ Apoptosis Detection Kit (terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling, TUNEL)
was from Chemicon International (Temecula, CA, USA).
DNeasy Blood & Tissue Kit was provided by Qiagen
(Hilden, Germany). The rabbit polyclonal antibody to
TNF-α receptor type 1 (TNF-R1) (human), mouse mono-
clonal antibody to Bax (mouse) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Therabbit monoclonal antibody to Bcl-2 was from Cell Signal-
ing Technology (Beverly, MA, USA). Pronase E and
DNase were obtained from Roche (Switzerland). Collage-
nase type IV was from Sigma (St. Louis, MO). Medium
199 (M199) and minimum essential medium eagle w/o Ca2+
(MEM) were from Gibco. OptiPrep™ was from Axis-shield,
Norway. N-acetylcystein (NAC) and Z-VAD-FMK were
from Sigma. All other chemicals used in the experiment
were of analytical grade.
Drugs
Fuzheng Huayu recipe (FZHY) was provided by Shanghai
Sundise Medicine Technology Development Co., Ltd.,
China (SFDA approval No: Z20050546) (Shanghai, China).
Its formula, extraction process and chemical fingerprint
have been described in detail [10].
Animals
C57BL/6 (B6) mice (8 weeks of age, with average body
weight of 23 ± 2 g) were purchased from the Experimental
Animal Center, Chinese Academy of Science (Shanghai,
China). All mice were housed in a specific pathogen-free
and controlled environment. All animal studies were per-
formed according to the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the
Ethics of Animal Experiments of Shanghai University of
Traditional Chinese Medicine, China.
Experimental protocol
Four experimental protocols were followed. Firstly, to
address the influence of FHZY on apoptosis of hepato-
cyte following CCl4-induced acute hepatic injury. Mice
were subcutaneously injected with 100% CCl4 3 ml/kg
body weight for one time, starting at 8 weeks of age.
Three days before the first CCl4 injection, once-daily
treatment with FZHY powder 4.0 g (crude drug)/kg or
NAC 0.1 g/kg body weight respectively was started and
mice were followed as noted in Figure 1. Eighteen hours
after the first CCl4 injection, mice were analyzed for liver
function, hematoxylin-eosin (HE) staining and immuno-
histochemical evaluation of apoptosis (Figure 1). Sec-
ondly, to focus on the effect of FHZY on established
liver fibrosis, mice were injected at 8 weeks of age with
100% CCl4 3 ml/kg body weight for the first time, then
50% CCl4/olive oil 3 ml/kg body weight, two times per
week for 8 weeks. Three days before the first CCl4 injec-
tion, once-daily treatment with FZHY powder 4.0 g
(crude drug)/kg or NAC 0.1 g/kg body weight respect-
ively was started and mice were followed as noted in
Figure 2. At 16 weeks of age, or 8 weeks following the
initial exposure to CCl4, mice were sacrificed for histo-
logical assessment of liver fibrosis, and immunohisto-
chemical evaluation of apoptosis (Figure 2). Thirdly, to
Figure 1 (See legend on next page.)
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Figure 1 Fuzheng Huayu recipe (FZHY) and N-acetylcysteine (NAC) attenuates hepatocyte apoptosis induced by CCl4. Mice were
respectively treated orally with FZHY (4.0 g/kg) or NAC (0.1 g/kg) daily for 3 d. Then, mice were subcutaneously injected with 100% CCl4 for
18 hours to develop acute liver injury (A). Liver sections were subjected to either hematoxylin-eosin staining to detect necrosis and inflammatory
cell infiltration (B, × 100) or to the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay to detect cell apoptosis
(C, × 200). (D) Serum ALT and AST levels in the four groups (Control group, n = 10; CCl4 treated, n = 11; FZHY treated, n = 15; NAC treated,
n = 15). (E) The apoptotic index (AI) of five high-power fields at × 400 magnification in each tissue specimen. (F) Necrosis and inflammatory cell
infiltration scores in the four groups (Control group, n = 10; CCl4 treated, n = 11; FZHY treated, n = 15; NAC treated, n = 15). (G) Quantitative ELISA
analysis of hepatic TNF α expression in the four groups (Control group, n = 10; CCl4 treated, n = 11; FZHY treated, n = 15; NAC treated, n = 15).
*P < 0.05,
**P < 0.01 vs. control group; #P < 0.05, ##P < 0.01 vs. CCl4 group.
Tao et al. BMC Complementary and Alternative Medicine 2014, 14:449 Page 4 of 13
http://www.biomedcentral.com/1472-6882/14/449detect the effect of FHZY on hepatocyte apoptosis in-
duced by Act D/TNF-α (Figure 3), After cultured for
24 hour, primary hepatocytes were treated with 10%
FZHY-medicated serum or 10% rats’ serum + 50 μM
Z-VAD-FMK for 18 h and then incubated with 200 ng/ml
ActD and 20 ng/ml TNF-α for another 6 h. Immunofluor-
escence, flow cytometry and DNA ladder for hepatocyte
apoptosis and immunoblotting for TNFR1, Bcl-2 and Bax
were also analyzed. Finally, to explore whether FZHY at-
tenuated hepatic fibrosis by inhibiting apoptosis of hepato-
cytes, we performed the subsequently experiments. At day
4 after isolation, primary HSCs were treated with the
DNA of apoptotic hepatocytes incubated by Act D/TNF-α
and 10% FZHY-medicated serum. Immunofluorescence
and immunoblotting for α-SMA and type I collagen in
HSCs were analyzed (Figures 4 and 5).
Histological and immunohistological analysis of liver
sections
Liver tissues were fixed with 10% formalin, embedded in par-
affin and cut into 4-μm sections stained with hematoxylin-
eosin (H&E). Necroinflammatory activity in hepatic tissue
was graded by a “blinded” liver pathologist according to
the Scheuer scoring system [18]. For quantitative assess-
ment of fibrosis, sections were stained with Sirius Red for
quantitative analysis of collagen content [19]. α-SMA, a
marker of hepatic stellate cells activation, was assessed by
staining with rabbit anti-α-SMA antibody (clone 1A4;
Dako, Glostrup, Denmark) and visualized with HRP la-
beled anti-rabbit antibody (ChemMate™ EnVision™ Detec-
tion Kit, Dako).
Analysis of serum transaminase activity and Alb level
The activities of serum alanine aminotransferase (ALT)
and aspertate aminotransferase (AST) and serum albu-
min (Alb) level were quantitated by following the in-
structions provided by the manufacturer, including use
of standardization [20].
Hydroxyproline assay
Hyp content of liver was assayed with HCl hydrolysis ac-
cording to a modification of method by Jamall et al. [21].
The Hyp content of the liver as an indirect measure oftissue collagen content was expressed as microgram per
gram of liver weight (μg/g).
TUNEL assay
For detection of cell apoptosis, TdT-mediated dUTP
nick end labeling (TUNEL) analysis was performed as
previously described [22]. In each tissue specimen, five
high-power fields at × 400 magnification were randomly
selected and the apoptotic index (AI) was calculated as the
percentage of positive cells, using the equation: AI = (number
of positive cells/total number of cells) × 100% [23].
Preparation of FZHY-medicated serum
FZHY powder was administered to the rats at a dose of
2 g (crude drug)/kg body weight by intragastic gavage
twice a day for 3 days. The rats were given FZHY 1 h be-
fore being sacrificed on the 4 th day. Blood samples were
collected under anesthesia. The samples were placed at
4°C for 4 h and then centrifuged at 3000 rpm for
20 min. The sera were inactivated at 56°C for 30 min
and then stored at −20°C for further use.
Primary hepatocytes and HSCs isolation and culture
Primary hepatocytes isolation. Male C57BL/6 mice men-
tioned above were used in this study. Primary hepato-
cytes were isolated using a two-step in situ collagenase
perfusion method. Briefly, the hepatic portal vein was
canulated in situ, then it was perfused with calcium and
magnesium-free Hanks’ salt solution for 10 minutes,
followed by 0.45–0.5 mg/mL of type IV collagenase solu-
tion at 37°C until the liver capsule was incised. After
perfusion, the thick fibrous connective tissue was dis-
carded and filtered cell suspensions were harvested. Pri-
mary hepatocytes were then collected by centrifugation
and seeded in M 199 containing 10% FBS. The viability
of the freshly isolated hepatocytes was determined by
trypan blue exclusion and cell samples with viability
greater than 90% were used in the subsequent assays.
Primary HSCs isolation. Sprague–Dawley rats (with
average body weight of 400 ± 30 g) were used in this
study. Primary HSCs were isolated from normal rat liver
by a two step pronase-collagenase perfusion and single-
step density gradient of OptiPrep™. Briefly, the liver were
perfused firstly with calcium and magnesium - free
Figure 2 (See legend on next page.)
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Figure 2 Fuzheng Huayu recipe (FZHY) and N-acetylcysteine (NAC) improves hepatic fibrosis. Mice were respectively treated orally with
FZHY (4.0 g/kg) or NAC (0.1 g/kg) daily for 3 d before CCl4 treatment. Then, mice were injected at 8 weeks of age with 100% CCl4 3 ml/kg body
weight for the first time, then 50% CCl4 /olive oil 3 ml/kg body weight, two times per week for 8 weeks to develop hepatic fibrosis (A). Liver
sections were subjected to either hematoxylin-eosin staining to detect inflammatory cell infiltration and necrosis (B, × 100) or to the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay to detect cell apoptosis (C, × 200) or to immunohistochemical staining
for α-SMA for detection of activated hepatic stellate cells (HSCs) (D, × 200) or to Sirius Red staining for detection collagen deposition (E, × 200).
(F) Serum ALT and AST levels and Alb content in the four groups (Control, n = 10; CCl4 treated, n = 11; FZHY treated, n = 11; NAC treated, n = 12).
(G) Hepatic Hyp content was determined using Jamall’s method. The Hyp content was increased significantly in CCl4 treated group compared with the
control group. FZHY or NAC treatment significantly decreased liver Hyp content. **P < 0.01 vs. control group; ##P < 0.01 vs. model.
Tao et al. BMC Complementary and Alternative Medicine 2014, 14:449 Page 6 of 13
http://www.biomedcentral.com/1472-6882/14/449solution for 10 min at 37°C, and then with Pronase E so-
lution (2.4 mg/ml) and collagenase IV solution (0.3–
0.45 mg/ml) for 10 min and 30 min respectively at 37°C,
the digested liver were excised, dispersed in serum-free
MEM,and filtered through gauze. The cells were mixed
with 12.25 ml Gey’s balanced salt solution (GBSS: Dis-
solve the following in 500 ml water: 7.0 g NaCl, 0.37 g
KCl, 70 mg MgSO4.7H2O, 220 mg) and 2.75 ml of 60%
(w/v) of OptiPrep™. The gradient was generated by pla-
cing 10 ml of GBSS on top of the liver cell mixture in a
50-ml centrifugation tube. After centrifugation (1,400 g,
20°C, 20 min) the cells were aspirated from above the
interface, washed once in serum-free MEM and subse-
quently cultured under an atmosphere of 5% CO2, 95%
air in 100-mm tissue culture dishes using M199 contain-
ing penicillin G 100 U/ml, streptomycin sulfate 100 U/ml
and 10% FBS. For immunofluorescent stain, cells were cul-
tured on 12-well plate. Cell viability was greater than 90%
as assessed by trypan blue exclusion. Purity was 90–95%
as assessed by immunoflurescent stain of Desmin.
Hepatocyte apoptosis determined by confocal
microscopy and flow cytometry analysis
Primary hepatocytes cultured on cover slips were washed
with cold PBS twice and incubated with FITC-labeled
Annexin V and propidium iodide (PI) for 2 min. After
washing twice with the binding buffer provided by the
manufacture, the cells were mounted with fluorecscence
compatible medium. View images immediately by con-
focal microscopy (TCS-SP2, Leica, Mannheim, Germany).
Primary hepatocytes in each group were harvested,
washed with cold PBS, and stained with Annexin V and
PI for 15 min in accordance with the manufacturer’s in-
structions. The analysis was performed with a FACScan
flow cytometer (BD Biosciences, San Jose, CA, USA)
using the Cell Quest software (BD Biosciences).
Preparation of apoptotic DNA from hepatocyte
In vitro experiment were performed referred to Watanabe
[4]. Primary hepatocytes were cultured in a 60 mm dish,
and when near confluent were exposed to 200 ng/ml ActD
and 20 ng/ml TNF-α referred to our previous work. Cell
apoptosis was evident 6 hours after exposure. At this time,
DNA was extracted by kits following the manufacturer’sinstructions. DNA was quantified and apoptosis was con-
firmed by running the extracted DNA on an agarose gel to
visualize the characteristic laddering of fragmented DNA.
Immunofluorescence for α -SMA
Indirect fluorescence immunostaining of α-SMA was
performed. Briefly, HSCs cultured on cover slips were
washed with cold PBS twice, fixed with 4% polyformal-
dehyde in PBS at room temperature for 15 min, and
permeabilized with 0.1% Triton X-100 in 0.1% sodium
citrate at room temperature for 15 min. The cells were
blocked with 5% bovine serum albumin in PBS buffer
for 30 min at room temperature and then incubated
overnight at 4°C with primary mouse monoclonal anti-
body to mouse α-SMA (1:100) (Sigma, USA). Then cells
were stained with Alexa Fluor® 488 goat anti-mouse IgG
(H + L) (1:100) (Invitrogen, USA). After washing, cells
were stained with Hoechst 33258 to visualize the nuclei.
Stained cells were mounted with antifade mounting
medium and viewed under fluorescence microscope
(Olympus, Japan).
Enzyme-linked immunosorbent assay for TNF α
The expression of TNF-α protein in the supernatant of
rat liver homogenate was determined using an Enzyme-
linked immunosorbent assay from ThermoFisher Scien-
tific Inc. according to the manufacturer’s protocol.
Western blot analysis
Cells were homogenized in RIPA buffer (50 mmol/L
Tris–HCl, 150 mmol/L NaCl, 1 mmol/L PMSF, 1 mmol/L
EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, pH 7.4), and the homogenate was centrifuged at
12,000 g for 30 min. The protein concentrations of super-
natant were determined by the BCA protein assay. All
procedures were performed at 4°C. The solubilized cell
samples, each containing 30 μg of protein, were subjected
to 10% SDS-PAGE gel electrophoresis in reducing and de-
naturing conditions and then transferred onto nitrocellu-
lose membrane. The membranes were then blocked with
5% nonfat milk in Tris- buffered saline containing 0.1%
Tween (TBST, 100 mmol/L Tris–HCl, pH 8.0, 150 mmol/L
NaCl, and 0.1% Tween 20) for 1 h at room temperature,
followed by incubation with primary antibodies overnight
Figure 3 Fuzheng Huayu recipe (FZHY) inhibits Act D/TNF-α induced hepatocyte apoptosis. Z-VAD-FMK (FMK) is a synthetic peptide that
irreversibly inhibits activity of caspase family proteases and blocks apoptosis, and was used as a positive control in this work. Twenty four hours
after plating, primary hepatocytes were pretreated with 10% FZHY medicated serum or 10% rats’ serum plus 50 μM Z-VAD-FMK for 18 h and then
incubated with 200 ng/ml ActD and 20 ng/ml TNF-α for 6 h. (A) Confocal microscopy observation of hepatocyte apoptosis stained by FITC
labeled Annexin V (green) and propidium iodide (PI) (red) (×400). (B) Cells were trypsinized and stained with Annexin V and PI followed by
analysis with flow cytometry. Early apoptotic cells (Annexin V positive and PI negative) were in the right lower quadrant. Late apoptotic or
necrotic cells were in the right upper quadrant. (C) The apoptotic index (AI) of five high-power fields at × 400 magnification of confocal
microscopic figures in Figure 3A. **P < 0.01 vs. control group; ##P < 0.01 vs. Act D/TNF-α treated group. (D) Primary hepatocytes were pretreated
with 10% FZHY medicated resum or 10% rats’ serum + 50 μM Z-VAD-FMK for 18 h and then incubated with 200 ng/ml ActD and 20 ng/ml TNF-α
for 6 h. Cells were harvested, and DNA was purified by the DNeasy Kit. DNA was separated on 1.5% agarose gel electrophoresis and visualized
under ultraviolet light. Lane 1, marker; lane 2, phosphate-buffered saline (PBS) treated cells; lane 3, PBS and Act D/TNF-α treated cells; lane 4, FZHY
and Act D/TNF-α treated cells; and lane 5, Z-VAD-FMK and Act D/TNF-α treated cells. Agarose gel electrophoresis showed that FZHY and
Z-VAD-FMK inhibited apoptosis of hepatocytes induced by Act D and TNF-α.
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Figure 4 Fuzheng Huayu recipe (FZHY) inhibits Act D/TNF-α induced hepatocyte apoptosis via regulating the apoptotic and anti-apoptotic
proteins in mitochondria. Primary hepatocytes were pretreated with 10% FZHY medicated resum or 10% rats’ serum plus 50 μM Z-VAD-FMK for 18 h
and then incubated with 200 ng/ml ActD and 20 ng/ml TNF-α for 6 h. (A) Western blot analysis of TNFR1, Bcl-2 and Bax in hepatocytes. TNFR1
expression was low in untreated hepatocytes, whereas TNFR1 expression increased after ActD and TNF-α stimulation. The expression of TNFR1 was
significantly down-regulated by FZHY or Z-VAD-FMK treatment. Similarly, the expressions of Bcl-2 and Bax were balanced by FZHY or Z-VAD-FMK
treatment. Graphic presentation of the relative expressions of TNFR1 (B) and Bcl-2 and Bax (C). Values were represented as the density of TNFR1, Bcl-2
or Bax vs. housekeeping gene GAPDH (%) from 3 samples. **P < 0.01 vs. control; ##P < 0.01 vs. Act D/TNF-α treated group.
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TNF-R1 (1:200), Rabbit monoclonal antibody to Bcl-2
(1:1000), Mouse monoclonal antibody to mouse Bax (1:200),
and GAPDH (Kangcheng, China), as housekeeping control.
Thereafter, the blots were washed with TBS-T 3 times,
followed by incubation with the second antibody (anti-
mouse or anti-rabbit horseradish peroxidase-conjugated
antibody, Santa Cruz) for 1 h at room temperature. After
washing, the blots were developed with SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific,
USA) and then exposed to X-ray films (Kodak, China) in
accordance with the manufacturer’s protocol.
Statistical analysis
Data are expressed as mean ± SD. Data were analyzed
using a one-way analysis of variance (ANOVA) as wellas the LSD test, and P < 0.05 was considered statistically
significant.
Results
FZHY attenuates hepatocyte apoptosis in CCl4 induced
mice
In a recent study, we induced hepatocyte apoptosis
in vivo through injection of Lipopolysaccharide (LPS)/D-
galactosamine (GalN) in mice [17]. FZHY treatment sig-
nificantly attenuated hepatocyte apoptosis as indicated
by TUNEL staining. FZHY exerted both anti-fibrotic
and anti-apoptotic functions, but whether the effect of
FZHY on liver fibrosis was primarily due to its inhibitory
effect on hepatocyte apoptosis. Here in order to make
this clear, we first studied acute liver injury by subcuta-
neously injecting CCl4 for one time and treating daily
Figure 5 The DNA of Apoptotic hepatocyte up-regulates α-SMA expression in rat HSCs and FZHY inhibited hepatocyte apoptosis and
the expressions of α-SMA and type I collagen in HSCs. (A) Fragmented apoptotic DNA in cultured hepatocytes was induced by 200 ng/ml
Act D and 20 ng/ml TNF-α. Lane 1, Marker, Lane 2; phosphate-buffered saline (PBS)-treated hepatocytes; Lane 3, Act D/TNF-α treated hepatocytes.
(B) Primary hepatocytes were incubated with or without 200 ng/ml ActD and 20 ng/ml TNF-α for 6 h. 100 μg/ml DNA from hepatocytes incubated
with PBS acted as a control. 25 ~ 100 μg/ml DNA from apoptotic hepatocyte stimulated α-SMA expression in rat HSCs in a dose dependent manner
(Immunofluorescence staining, × 400). (C) Western blot analysis of expressions of α-SMA and type I collagen in rat HSCs. (D) Graphic presentation of
the relative expressions of α-SMA and type I collagen. The values were represented as the density of α-SMA and collagen I vs. housekeeping gene
GAPDH (%) from 3 samples. (E) Primary hepatocytes were incubated with or without 200 ng/ml ActD and 20 ng/ml TNF-α for 6 h. Then, 100 μg/ml
DNA from apoptotic hepatocytes was added into HSCs after culture for 4 days. 100 μg/ml DNA from hepatocytes incubated with PBS acted as a
control. The apoptotic DNA from hepatocytes treated by FZHY or Z-VAD-FMK (FMK) had less stimulating effects on α-SMA expression in HSCs
(Immunofluorescence staining, × 400). **P < 0.01 vs. Control; ##P < 0.01 vscpc Act D/TNF-α group.
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less necrosis and inflammatory cells infiltration were
seen in FZHY or NAC-treated mice compared with
CCl4 treated mice (P < 0.05) (Figure 1B & F). FZHY or
NAC treatment markedly down-regulated hepatocyte
apoptosis in the liver of mice injected with CCl4 (P < 0.05)
(Figure 1C). As shown in Figure 1D, there were no signifi-
cant differences in ALT and AST levels among FZHY-treated group, NAC-treated group and CCl4 treated group
(P >0.05). Then, the concentration of TNF-α in liver tissue
was detected by ELISA. TNF-α level was very low in nor-
mal liver. After a single dose of CCl4 treatment, the ex-
pression of TNF-α protein was significantly increased, and
FZHY or NAC treatment attenuated TNF-α expression in
CCl4 treated mice (P < 0.05) (Figure 1G). Quantitation of
the apoptotic hepatocytes revealed that FZHY or NAC
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in CCl4-induced acute liver injury in mice (P < 0.05)
(Figure 1E).
FZHY alleviates liver injury and hepatic fibrosis induced
by CCl4 in mice
We next studied CCl4-induced liver fibrosis by subcuta-
neously injecting CCl4 for 8 weeks and treating daily
with FZHY or NAC (Figure 2A). Liver sections revealed
less vacuolated cells and significantly improved portal
inflammation in the FZHY or NAC treated mice com-
pared to controls (Figure 2B). As shown in Figure 2F,
ALT and AST levels were slightly lower and Alb content
was higher in FZHY-treated mice compared with control
(P < 0.05). TUNEL assay revealed that apoptotic cells
were not significantly different between FZHY or NAC
treated and untreated mice with or without CCl4
(Figures 2C and 1E). Sirius red staining showed that
subcutaneous injection of CCl4 in mice for 8 weeks de-
veloped collagen deposition, false lobules formation.
Notable reduction of the thickening of the collagen bun-
dles was seen in FZHY or NAC-treated mice compared
with control (Figure 2E). Immunohistochemical analysis
revealed that the expression of α-SMA was low in nor-
mal liver, whereas it was prominent in mice receiving
CCl4 injection, and FZHY or NAC treatment attenuated
α-SMA expression (Figure 2D). To evaluate the progres-
sion of fibrosis in a quantitative manner, hepatic hydro-
xyproline (Hyp) content was measured. Liver collagen
content, expressed as microgram (μg) of Hyp/gram (g) of
liver tissue, was shown in Figure 2G. Hyp content in the
CCl4-treated mice was approximately 202% of that of the
control group (P < 0.01), suggesting abundant accumula-
tion of collagen in CCl4 induced mice. It was consistent
with the observation of marked fibrosis and accumulation
of collagen bundles in CCl4-induced mice by histo-
pathological examination. There was a significant de-
crease (P < 0.01) in liver Hyp content in FZHY or NAC
treated mice, suggesting that FZHY or NAC ameliorated
hepatic collagen deposition in CCl4-induced liver injury.
FZHY attenuates hepatocyte apoptosis by regulating
apoptotic mitochondria pathway
To detect the effect of FZHY on hepatocyte apoptosis,
primary hepatocytes were incubated with Act D/TNF-α
for 6 hours (Figure 3). The cleavage of chromosomal
DNA into fragments is a biochemical hallmark of apop-
tosis. Although it has been documented that hepatic
apoptosis is not always associated with DNA fragmenta-
tion [24], typical DNA ladder was shown with agarose
gel electrophoresis which provided additional evidence
in support of cell apoptosis after exposure to Act D/
TNF-α (Figure 3). Confocal microscopy showed that few
apoptotic hepatocytes were seen in control group, whilea large number of hepatocytes developed apoptosis after
6 hours incubation with Act D and TNF-α, FZHY treat-
ment significantly reduced the amount of apoptotic
hepatocytes (P < 0.01) (Figure 3A and C). Similarly, as
shown in Figure 3B with flow cytometry, only 3.6% of
hepatocyte apoptosis was seen in the control group,
while approximately 50% of hepatocyte developed early
or late apoptosis after induction by Act D and TNF-α,
FZHY or Z-VAD-FMK treatment reduced 30% of
hepatocyte apoptosis. As shown in Figure 3D, the ap-
pearance of typical DNA ladder determined by gel
electrophoresis confirmed the existence of apoptotic
hepatocyte after 6 hours exposure to ActD and TNF-α.
FZHY or Z-VAD-FMK treatment markedly reduced hep-
atocyte apoptosis incubated by ActD/TNF-α. TNF-α sig-
naling in hepatocyte apoptosis was well reviewed in
many documents [25,26]. Here the mitochondria path-
way was selected to observe whether FZHY regulation
was involved. Western blot analysis showed that FZHY
or Z-VAD-FMK treatment significantly down-regulated
TNFR1 expression compared with controls (P < 0.05)
(Figure 4A and B). Similarly, the expressions of Bcl-2
and Bax were balanced by FZHY or Z-VAD-FMK treat-
ment (P < 0.01) (Figure 4A and 4C).
The DNA from TNF-α/Act D treated hepatocytes stimulates
HSCs activation
Since FZHY exerted beneficial effects on ameliorating
hepatocyte apoptosis and hepatic fibrosis in CCl4-injected
mice, we were eager to know whether or not the anti-
hepatocytic apoptosis-effect of FZHY was one of its mech-
anisms against liver fibrosis. To answer this question, we
carried out the in vitro experiment that the DNA from
TNF-α/Act D treated hepatocytes was added into pri-
mary isolated HSCs at day 4 after plating. As shown in
Figure 5A, the appearance of typical DNA ladder deter-
mined by gel electrophoresis confirmed the existence of
apoptotic hepatocyte DNA after 6 hours exposure to
ActD and TNF-α. After co-incubation with 25 ~ 100 μg/ml
apoptotic DNA fragmentation for 24 hours, the expres-
sions of α-SMA in HSCs were unregulated in a dose
dependent manner (Figure 5B), which indicated apoptotic
hepatocyte DNA stimulated HSCs activation.
FZHY-treated hepatocyte apoptotic DNA inhibits HSCs
activation
However, it was not clear whether FZHY inhibiting
HSCs activation correlated with its inhibiting hepatocyte
apoptosis. Then, primary HSCs at day 4 after plating
were incubated with 100 μg/ml purified DNA from each
group. Immunofluorescence and western blotting ana-
lysis revealed that the expression of α-SMA was weak in
HSCs incubated with 100 μg/ml control DNA, whereas
it was prominent in HSCs incubated with 100 μg/ml
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pression, the expression of collagen I was markedly in-
creased in HSCs incubated with 100 μg/ml apoptotic
DNA compared with that incubated with control DNA.
The apoptotic DNA of hepatocytes treatment with
FZHY or VAD-FMK attenuated the expressions of α-
SMA and type I collagen in HSCs (P < 0.01) (Figure 5C
and D). The results indicated that FZHY inhibiting
HSCs activation correlated with its inhibiting hepatocyte
apoptosis.
Discussion
Apoptosis is an active form of cell death that involves
programmed cellular machineries leading to a progres-
sive self-destruction of the cell. In contrary to necrosis,
it can affect individual cells within a cell population. It is
characterized by chronological alteration of intracellular
biochemical signaling pathways followed by cellular
morphological changes, DNA fragmentation, perturb-
ation of mitochondrial membrane function and changes
in the plasma membrane [27]. Hepatocyte apoptosis,
one of the ubiquitous features of chronic and acute liver
injuries, is reported to associate with liver fibrosis
tightly. Proapoptotic stimulus induces hepatocyte apop-
tosis, meanwhile, the apoptotic cells release lipid signals
for their uptake by kupffer cells and HSCs. Engulfment
of the apoptotic bodies by HSCs and kupffer cells en-
hances their expression of pro-fibrogenic genes and
death ligands (e.g., FasL). Persistent activation of HSCs
and kupffer cells promotes further hepatocyte apoptosis,
which culminates in hepatic inflammation, with gener-
ation of CXC chemokines (interleukin-8, macrophage in-
flammatory protein-2, et al.) and further HSC activation
and liver fibrosis in a feed-forward-loop process [28].
The growing panoply of interactions between hepato-
cyte apoptosis, inflammatory, and fibrotic responses has
therapeutic implications. For example, small molecule
caspase inhibitors currently are being developed for clin-
ical use [29-31], which could reduce hepatocyte apop-
tosis thereby attenuating inflammation, reducing HSC
activation, and decreasing fibrosis. Acute and chronic
liver injury result in increased local and systemic concen-
trations of transforming growth factor-beta 1 (TGF-β1)
[32], a potent fibrogenic cytokine. N-acetylcysteine (NAC)
is an antioxidant, a precursor of reduced glutathione, and
an inhibitor of the profibrotic cytokine TGF-β1. NAC has
been shown to prevent damage to DNA and proteins
caused by mutagens and carcinogens and diminish apop-
tosis. Another study has suggested that NAC prevents ex-
perimental cirrhosis by two mechanisms: by preventing
oxidative stress and by downregulating the profibrogenic
cytokine TGF-β1 [33]. NAC is used as a control to prevent
apoptosis in vivo study, which is quite popular for its abil-
ity to minimize oxidative stress and the downstreamnegative effects thought to be associated with oxidative
stress. Carbon tetrachloride (CCl4) -induced liver injury is
characterized by oxidative stress and fibrosis. In our
current study, mice injected with CCl4 showed a charac-
teristic of massive hepatocyte apoptosis in early stage of
liver injury (Figure 1) and severe hepatic fibrosis in later
stage (Figure 2). In this work we found that serum ALT
and AST levels increased, the expression of TNF-α protein
in liver tissue was significantly increased, hepatic paren-
chyma was distorted and vacuolar degeneration and ne-
crosis of the hepatocytes (visualized by H&E stain) and
hepatocyte apoptosis (detected by TUNEL assay) in-
creased notably in acute liver injury induced by CCl4 in-
toxication. The results showed that FZHY and NAC
effectively attenuated CCl4-induced acute liver injury and
hepatocyte apoptosis (Figure 1). After 8 weeks of CCl4 in-
toxication, mice developed severe hepatic fibrosis, with
obvious fibrotic septa and α-SMA expression, diminished
apoptotic response and increased Hyp content. Adminis-
tration of FZHY and NAC reduced collagen accumulation
as evidence by marked reduction of Hyp content (Figure 2).
This might be partly attributed to FZHY protecting hepa-
tocytes from apoptosis in early stage of liver injury.
Excessive hepatocyte apoptosis is thought to lead to
liver dysfunction and damage in a variety of liver dis-
eases, and this process may occur during the initiation
and/or progression of disease. Our previous work showed
FZHY could protect hepatocytes from apoptosis and ne-
crosis in acute liver injury induced by lipopolysaccharide
(LPS)/D-galactosamine (D-GalN), and the mechanisms in
part were associated with regulations of apoptotic factors—
Bcl-2 and Bax [17]. However, whether or not FZHY
affected, as well as how it might affect, the apoptotic sig-
naling in primary hepatocytes were unknown. In subse-
quent experiments in vitro, primary mouse hepatocytes
were used, and cells were stimulated by Act D plus TNF-α.
Z-VAD-FMK, an irreversible general caspase inhibitor that
irreversibly binds to the catalytic site of caspase proteases
[34], was used as a control to prevent apoptosis in vitro
study. In this study, we initially observed that a large num-
ber of hepatocytes developed apoptosis after 6 hours incu-
bation with Act D plus TNF-α. Various methodologies
were then used to assess the effects of FZHY on hepato-
cytes apoptosis, including flow cytometry, DNA electro-
phoresis and Annexin V and PI staining. Our results
confirmed that FZHY had the same effect on hepatocyte
apoptosis as Z-VAD-FMK (Figure 3A-D). Together, these
observations suggested that FZHY could effectively inhibit
hepatocyte apoptosis both in vivo and in vitro. It was well
documented that the apoptotic signal induced by Act D
plus TNF-α was initially transduced by an extrinsic signal-
ing pathway. TNF-α binds to two cell surface receptors
known as TNF-R1 and TNF-R2, with the apoptotic effects
of TNF-α being mainly mediated by TNF-R1 [35]. It is well
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requires the activation of mitochondria [36]. The increase
in mitochondrial membrane permeability is a pivotal event
in its activation. This process is regulated by the Bcl-2
family of proteins that are divided into proapoptotic and
anti-apoptotic proteins and are best described as media-
tors of mitochondrial dysfunction [37]. Therefore, we
attempted to determine whether FZHY exerted an effect
on expressions of TNF-R1, Bcl-2 and Bax. The findings
obtained by immunoblotting showed that FZHY and
Z-VAD-FMK dramatically downregulated expressions
of TNF-R1 and Bax and upregulated Bcl-2 expression.
In the present study, mice injected by CCl4 showed a
characteristic of massive hepatocytes apoptosis in early
stage of liver injury and severe hepatic fibrosis in later
stage. Hepatocyte apoptosis, one of the ubiquitous fea-
tures of acute and chronic liver injuries, is reported to
associate with fibrosis tightly. A hepatocyte specific dis-
ruption of Bcl-xL, an antiapoptotic member of the Bcl-2
family, leads to continuous hepatocyte apoptosis and
later liver fibrotic responses. In contrast, inhibition of
hepatocyte apoptosis by caspase inhibitor leads to less liver
injury and fibrosis [30]. Researchers find that phagocytosis
of hepatocyte-derived apoptotic bodies by HSCs is profi-
brogenic as it induces collagen α1 (I) and TGF-β1 upregu-
lation [38]. DNA extracted from apoptotic hepatcoytes
induces differentiation of mouse and human HSCs [4].
These data suggest that inhibiting hepatocyte apoptosis
may be one of the mechanisms for attenuating hepatic fi-
brosis by drugs. The anti-apoptotic effects and mecha-
nisms of FZHY on hepatocytes were well elucidated in
both animal and cell models. Meanwhile, we also con-
firmed that FZHY markedly decreased the expression of
α-SMA in the fibrotic liver examined by immunohisto-
chemical staining, as well as attenuated extracellular
matrix (ECM) deposition in liver. However, whether or
not FZHY prevented HSC activation and hepatic fibrosis
through its inhibitory effect on hepatocyte apoptosis? Our
results showed that the DNA of apoptotic hepatocytes
stimulated HSC activation in a dose dependent manner,
and the attenuated hepatocyte apoptosis with FZHY or
Z-VAD-FMK treatment reduced HSC activation which
reduces ECM deposition. The exact mechanism for this
occurrence is not known.
Conclusions
FZHY suppressed hepatocyte apoptosis elicited by CCl4
in vivo or ActD/TNF-α in vitro through regulating medi-
ators in death receptor and mitochondrial pathways, and
this action on hepatocyte apoptosis might play an im-
portant role on HSC activation and liver fibrosis.
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